隶属于 colorado state university system
相关临床试验
116
19 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1870
进行中（未招募）
11
9.5%
已完成
76
65.5%
Enrolling By Invitation
1
0.9%
尚未招募
7
6.0%
招募中
12
10.3%
终止
4
3.5%
Unknown
2
1.7%
撤回
3
2.6%
暂无批准数据
- Researchers at Colorado State University are conducting a clinical trial combining CAR T-cell therapy with verdinexor in dogs with naturally occurring brain tumors to develop treatments for pediatric high-grade gliomas. - The combination therapy aims to overcome the immune-suppressive tumor microenvironment that limits CAR-T effectiveness in solid brain tumors, unlike their success in blood cancers. - Pediatric high-grade glioma patients rarely survive a year after diagnosis, representing a critical unmet medical need with limited treatment options beyond radiation therapy. - The canine trial results could provide preliminary safety and effectiveness data to support future clinical trials in children at the University of Colorado Anschutz Cancer Center.
- Renovare Therapeutics launched from stealth mode in April 2026, collaborating with University of Colorado Boulder on a $33.5 million ARPA-H contract to develop regenerative osteoarthritis therapies. - The company's platform technologies include controlled drug delivery systems, novel gene therapies, and advanced regenerative biomaterials designed to halt and reverse osteoarthritis disease progression. - Lead product candidates are advancing toward IND-enabling studies in 2026, targeting the more than 32 million Americans affected by osteoarthritis with potentially transformative regenerative treatments. - The leadership team includes industry veterans with experience guiding nine products through clinical development and regulatory approvals, culminating in over $18 billion in acquisitions.
- Colorado State University researchers found molnupiravir achieved 77% survival rates in 73 cats with naturally occurring FIP during a 12-week treatment trial. - The antiviral provides a second treatment option alongside GS-441524, particularly for cats who don't respond to or relapse after initial therapy. - Side effects were manageable and did not require treatment discontinuation, with 12% of survivors experiencing relapse but surviving after additional treatment. - The breakthrough offers veterinarians expanded therapeutic options for a disease that was historically fatal in cats.
- A Phase 1 clinical trial has begun testing a novel cancer vaccine that uses the Mirasol process to inactivate cancer cells while preserving their immune-stimulating properties. - The trial involves eight patients with recurrent ovarian cancer who will receive personalized vaccines created from their own tumor cells treated with UV light and riboflavin. - The approach aims to preserve neoantigens that conventional treatments destroy, potentially offering a more effective way to stimulate immune responses against cancer. - Expert opinions are divided, with some supporting the whole-cell approach while others cite the historical failure of similar strategies.
- The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. - North Carolina State University is exploring a novel treatment approach for oral cancer in cats. - Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. - Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.
- The USDA has granted conditional license for Elanco's Canine Parvovirus Monoclonal Antibody, marking the first approved therapeutic solution to treat canine parvovirus. - In efficacy studies, all 28 treated puppies survived with significantly faster recovery times for vomiting, inappetence, and lethargy compared to traditional supportive care. - The single intravenous dose treatment could reduce hospitalization costs and make parvovirus treatment more accessible to pet owners who previously couldn't afford intensive care. - This breakthrough represents the first monoclonal antibody treatment for Elanco and addresses a critical unmet need in veterinary medicine for a disease with over 90% fatality rate if untreated.
